GlobeNewswire

Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial

Share

Press Release

17 December 2020

Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial

-- Topline results on safety and dosing from Phase Ib portion of trial expected during Q3 2021 --

-- Phase II portion of trial can initiate following selection of dose regimen from Phase Ib trial --

Immunicum AB (publ; IMMU.ST) announced today the completion of patient recruitment for the Phase Ib portion of the ongoing ILIAD (ILIxadencel in combination with checkpoint inhibitors in ADvanced cancer patients) trial. The primary objective of the Phase Ib study is to evaluate the safety and tolerability as well as define the dose regimen for Immunicum’s lead cell-based candidate, ilixadencel, in combination with the checkpoint inhibitor (CPI), Keytruda® (pembrolizumab), in a total of 21 patients.The follow-up period for the Phase Ib portion of the trial will include imaging of up to 6 months for evaluation of safety, dosing and signs of efficacy. Topline results of the Phase Ib trial are expected during the third quarter of 2021.

“Successfully finishing patient recruitment for the Phase Ib portion of the ILIAD trial stands as an important achievement, particularly during a year in which clinical trials, patient recruitment and standard operations have been impacted by the Covid-19 pandemic,” commented Sven Rohmann, MD, Ph.D., CEO of Immunicum. “The completion of this milestone brings us one step closer to the topline data readout expected during Q3 next year, which will give us further insight into the potential of ilixadencel in a range of indications and in combination with checkpoint inhibitors. The Phase Ib/II ILIAD trial remains a critical piece of our clinical development strategy, and we look forward to continuing to provide updates on our newly expanded clinical pipeline.”

The Phase Ib/II ILIAD combination trial includes patients who are candidates for pembrolizumab therapy in its approved label by the FDA, which includes, among others, the tumor types head and neck squamous cell carcinoma, non-small cell lung cancer and gastric and gastroesophageal junction adenocarcinoma. In terms of dosing, three patients were planned to receive two intratumoral doses of 3 million cells, six patients two doses of 10 million cells, six patients three doses of 10 million cells and the last six patients will receive one dose of 20 million cells followed by two doses of 10 million cells. Throughout the duration of the trial, the Dose Escalation Committee (DEC) has assessed ilixadencel’s safety profile. The last update from the DEC in October confirmed there had been no dose-limiting toxicities. The Phase II portion of the ILIAD trial can subsequently continue with the selected dose regimen from the Phase Ib.

About ilixadencel
Ilixadencel is an off-the-shelf cell-based cancer immunotherapy developed for the treatment of solid tumors. Its active ingredient is activated allogeneic dendritic cells, derived from healthy blood donors. Injection of these cells in the patient’s tumor generates an inflammatory response which in turns leads to tumor-specific activation of the patient’s cytotoxic T cells. To-date ilixadencel has been tested in a range of clinical trials in various solid tumor indications including metastatic Renal Cell Carcinoma (mRCC), hepatocellular carcinoma (HCC) and gastrointestinal stromal tumors (GIST) and in combination with several standard-of-care cancer therapies such as the tyrosine kinase inhibitors Sutent® (sunitinib) and Stivarga® (regorafenib), and the checkpoint inhibitor Keytruda® (pembrolizumab). Ilixadencel has consistently maintained a positive safety and tolerability profile and demonstrated initial signs of efficacy as seen in the randomized Phase II MERECA trial. Ilixadencel is currently moving towards late-stage clinical development.

About ILIAD
Immunicum has named its multi-indication Phase Ib/II checkpoint inhibitor (CPI) combination trial ILIAD. The name represents ILIxadencel in combination with checkpoint inhibitors in ADvanced cancer patients. The trial will enroll patients with different cancer indications, including head and neck squamous cell carcinoma, non-small cell lung cancer and gastric and gastroesophageal junction adenocarcinoma.

For more information, please contact:

Sven Rohmann, CEO, MD, Ph.D.
Telephone: +46 8 732 8400
E-mail: info@immunicum.com

Investor Relations

Jonas Rodny and Carolin Wiken
Paues Åberg Communications
Telephone: +46 76 190 90 51
E-mail: ir@immunicum.com

Media Relations

Joanne Tudorica and Sophia Hergenhan, Ph.D.
Trophic Communications
Telephone: +49 171 351 2733
E-mail: ir@immunicum.com

About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The Company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

AS PRFoods unaudited preliminary consolidated turnover of the 2nd quarter and 6 months of the 2020/2021 financial year17.1.2021 20:58:59 CETPress release

PRFoods unaudited preliminary consolidated turnover in the 2nd quarter of the financial year 2020/2021 amounted to 17.07 million euros. Compared to the previous quarter i.e. the 1st quarter, the sales increased by 33.9%, (1Q 2020/2021: 12.74 million euros), with retail sector increased by 30.7%, wholesale by 43.6% and HoReCa sector by 14.2%. Compared to last year same period, sales decreased by 32.9% (2Q 2019/2020: 25.43 million euros), decrease in HoReCa by 52.7% and in wholesale by 60.9%. Sales increased in retail sector by 3.2% Indrek Kasela, CEO, PRFoods: „The impact of COVID-19 continues in fish sector and as we noted in last sales announcement, HoReCa sector which gives ca 1/3 of salmon- and troutbusiness both globally and regionally, will not recover to previous levels in next 12 months. End of the year brought Christmas lockdowns around Europe, for example UK was in full lockdown. In December, price of fresh salmon and trout was at historic 12 year low, which is total anomaly,

Announcement | MCH Group | Board of Directors and Executive Board16.1.2021 19:00:00 CETPress release

MCH Group: Appointments to the Board of Directors and Executive Board Andrea Zappia proposed as new chairman of the Board of Directors, Marco Gadola foreseen as Vice Chairman Beat Zwahlen appointed as interim CEO and Michael Hüsler as new CFO Bernd Stadlwieser leaving the company by mutual agreement Following completion of the capital increases, the partial renewal of the Board of Directors of MCH Group Ltd., which was approved by the General Meeting on 27 November 2020, took effect on 21 December 2020: James Murdoch, Jeffrey Palker and Eleni Lionaki have taken up their mandates as successors to Karin Lenzlinger Diedenhofen, André Odermatt and Tanja Soland respectively. Today, the Board of Directors announces further intended personnel renewals: The Board of Directors will propose Andrea Zappia and Marco Gadola for election as new members of the Board of Directors at the General Meeting on 28 April 2021. Andrea Zappia will also be proposed for election as Chairman and successor to Ulri

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS15.1.2021 16:20:00 CETPress release

Bid procedure, 2021-01-18BillsSWEDISH T-BILL: SE0014555991. 2021-06-16 SWEDISH T-BILL: SE0014808747, 2021-09-15 Bid date2021-01-18Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0014555991: 500 mln SEK +/-250 mln SEK SE0014808747: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0014555991: 500 mln SEK per bid SE0014808747: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-01-20Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-01-15 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS15.1.2021 16:20:00 CETPress release

Anbudsförfarande kommuner och regioner, 2021-01-19BondsFloating-rate Notes(FRN) issued in SEK by Municipalities or Regions with maturity in: 2023 The following issuers are accepted for delivery: Borås Stad Göteborgs Stad Helsingborgs Stad Huddinge Kommun Lunds Kommun Malmö Stad Norrköpings Kommun Region Skåne Stockholms Stad Region Stockholm Sundsvalls Kommun Södertälje Kommun Täby Kommun Uppsala Kommun Västerås Stad Örebro Kommun Östersunds Kommun Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after: 2021-01-08BidsBids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se Bid date2021-01-19Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 1000 +/- 1000 millionHighest permitted bid volume (corresponding nominal amount)The total bid volume from

CONDITIONS FOR PURCHASES OF CORPORATE BONDS15.1.2021 16:20:00 CETPress release

Bid procedure, 2021-01-20BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: AKELIUS RESIDENTIAL AB: XS1692931980, 2021-10-04 AKELIUS RESIDENTIAL AB: XS1889043359, 2023-10-03 FASTIGHETS AB BALDER: SE0013359726, 2022-07-01 FASTIGHETS AB BALDER: SE0012675940, 2022-01-28 WILLHEM AB: SE0012193985, 2025-02-22 WILLHEM AB: SE0011088921, 2022-01-11 LUNDBERGFORETAGEN AB: SE0012676666, 2024-12-06 LUNDBERGFORETAGEN AB: SE0012676609, 2025-11-13 TELE2 AB: XS2187707463, 2025-06-10 TELE2 AB: XS1571151627, 2023-02-24 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2020-12-20Bid date2021-01-20Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS1692931980: 30 mln SEK +/-30 mln SEK XS1889043359: 30 mln SEK +/-30 mln SEK SE0

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS15.1.2021 16:20:00 CETPress release

Bid procedure, 2021-01-21BondsSTADSHYPOTEK AB: 1590. SE0012676690. 2025-09-03 NORDEA HYPOTEK AB: 5534, SE0012230415, 2024-09-18 SKANDINAVISKA ENSKILDA: 576, SE0010049841, 2023-12-20 DANSKE HYPOTEK AB: 2312, SE0011116474, 2023-12-20 LANSFORSAKRINGAR HYPOTEK: 518, SE0011309244, 2025-09-17 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 SWEDBANK HYPOTEK AB: 194, SE0012142206, 2024-09-18 Bid date2021-01-21Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1590: 1500 mln SEK +/-500 mln SEK 5534: 1300 mln SEK +/-500 mln SEK 576: 900 mln SEK +/-450 mln SEK 2312: 400 mln SEK +/-200 mln SEK 518: 800 mln SEK +/-400 mln SEK 146: 800 mln SEK +/-400 mln SEK 194: 1300 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)1590: 1500 mln SEK per bid 5534: 1300 mln SEK per bid 576: 900 mln SEK per bid 2312: 400 mln SEK per bid 518: 800 mln SEK per bid 146: 800 mln SEK per bid 194: 1300 mln SEK per bid Lowest permitted bid volume

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS15.1.2021 16:20:00 CETPress release

Bid procedure, 2021-01-22BondsSWEDEN I/L BOND: 3112. SE0008014062. 2026-06-01 SWEDEN I/L BOND: 3111, SE0007045745, 2032-06-01 Bid date2021-01-22Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3112: 500 mln SEK +/-250 mln SEK 3111: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)3112: 500 mln SEK per bid 3111: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNo later than 10.10 (CET/CEST) on the Bid dateDelivery and payment date2021-01-26Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-01-15 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be r